Risk of new-onset diabetes varies with different statins
Eliano Pio Navarese, M.D., Ph.D., of Nicolaus Copernicus University in Poland, and colleagues conducted a network meta-analysis of 17 randomized, controlled trials involving 113,394 patients to examine the impact of different types and doses of statins on new-onset DM.
The researchers found that, in the comparison of statins versus placebo, the lowest risk for new-onset DM was seen for plavastatin 40 mg/day (odds ratio, 1.07; 95 percent credible interval, 0.86 to 1.30). In contrast, rosuvastatin 20 mg/day correlated with a greater risk of DM (odds ratio, 1.25; 95 percent credible interval, 0.82 to 1.90), while atorvastatin 80 mg/day exhibited intermediate risk (odds ratio, 1.15; 95 percent credible interval, 0.90 to 1.50). Similar findings were seen at moderate doses of statins.
"The findings of this large network meta-analysis are the first to provide information on the specific risk for DM associated with different types and doses of statins," the authors write. "If the findings of this network meta-analysis were confirmed in powered head-to-head comparisons, they would have important implications for the future management of millions of individuals receiving statins worldwide; indeed, a new scenario of statin therapy could be envisaged in which personalized statin therapy might emerge as the most effective and safest strategy."
Full Text (subscription or payment may be required)